Sentinel Diagnostics
- Company typePrivate
- Founded2009
- HeadquartersMilano, Italy
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
Sentinel Diagnostics firmographics
Firmographics- Name
- Sentinel Diagnostics
- Legal name
- SENTINEL CH. SpA
- Website
- https://sentineldiagnostics.com
- Company type
- Private
- Founded year
- 2009
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Ownership category
- akta.pro rank
Sentinel Diagnostics industry classification
Industry- Product category
- In Vitro Diagnostics
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- IVD Reagents, Assay Kits & Consumables (Non-instrument) (HLAHAAAM)
- akta.pro secondary industry
- Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls) (HLAAAMAL)
Keywords
Where Sentinel Diagnostics is headquartered
LocationHeadquarters
- HQ city
- Milano
- HQ country
- Italy
- HQ region
- Europe
Offices1 record
Markets served
Sentinel Diagnostics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Technology or R&D, Personnel, Marketing or Sales
Revenue model
- IVD Products Manufacturing and Sales: Sentinel Diagnostics generates revenue through the research, development, and manufacturing of In Vitro Diagnostic products. Product lines include molecular diagnostics (STAT-NAT kits for COVID-19, virology, VRE, parasitology), clinical chemistry, FIT (Fecal Immunochemical Test) line, and laboratory reagents. Products are sold directly to clinical laboratories and healthcare facilities.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Quote-based pricing for clinical laboratories |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Sentinel Diagnostics product offering
Product offeringCore offering
Sentinel Diagnostics researches, develops, and manufactures In Vitro Diagnostic (IVD) medical devices for clinical laboratories. Its portfolio includes proprietary lyophilized real-time PCR kits (STAT-NAT®) for molecular diagnostics, fecal immunochemical tests (FIT line) for colorectal cancer screening, clinical chemistry reagents, and automated instruments (SENTiNAT®, SENTiFIT®). Products are sold directly to clinical laboratories and healthcare facilities, primarily in the EU and selected international markets.
Product overview
Sentinel Diagnostics is a leader in Research and Development and Manufacturing of IVD (In Vitro Diagnostic) products based in Milan, Italy. The company operates three main product lines: (1) STAT-NAT® line featuring proprietary lyophilized real-time PCR technology for molecular diagnostics with room-temperature stable reagents, including COVID-19 molecular and serological assays, virology panels, healthcare-associated infection tests (VRE), and parasitology kits, supported by the SENTiNAT® instrument family (200, MICRO, X48); (2) FIT line providing Fecal Immunochemical Tests (FOB Gold®, CALiaGold®, PYLiaGold) for colorectal cancer screening, run on SENTiFIT® 270 automated analyzers; and (3) Laboratory line encompassing molecular biology reagents, clinical chemistry, dedicated reagents, and chromatography products acquired through Eureka S.r.l. The company also offers lyophilization services. Sentinel Diagnostics acquired Eureka S.r.l. in February 2023 to expand its diagnostic portfolio and assay offerings for clinical laboratories.
Differentiator
Problem solved
Functional benefit
Brands
- STAT-NAT®: Stabilized Amplification Technology - proprietary technology that stabilizes enzyme activity for long-term storage without temperature-controlled requirements
- FOB Gold®
- CALiaGold®
- PYLiaGold
- SENTiFIT®
- SENTiFOB®
- SENTiNAT®
Products and services
- STAT-NAT® molecular diagnostics line Proprietary lyophilized real-time PCR technology platform with room-temperature stable reagents for molecular diagnostics. Includes kits for COVID-19, virology, healthcare-associated infections, and parasitology applications, sold to clinical laboratories.
- FIT line (Fecal Immunochemical Test) Fecal Immunochemical Test (FIT) product line for colorectal cancer screening, including FOB Gold®, CALiaGold®, and PYLiaGold assays paired with SENTiFIT® instruments, sold to clinical laboratories and screening programs.
- STAT-NAT® COVID-19 MULTI Lyophilized one-step multiplex Real-Time RT-PCR mix for qualitative detection of SARS-CoV-2 RNA in human respiratory tract specimens, available in all-in-one tube and high-throughput formats for clinical laboratories.
- STAT-NAT® Pluri CoV-2-FLU-RSV Multiplex Real-Time RT-PCR for simultaneous qualitative detection of SARS-CoV-2, Influenza A&B, and RSV in human respiratory specimens in a single reaction, used by clinical laboratories for respiratory pathogen differentiation.
- STAT-NAT® SARS-CoV-2 (3-gene) 3-gene based Real-Time RT-PCR kit for qualitative detection of SARS-CoV-2 targeting RdRp, N, and E genes, designed to be unaffected by virus mutations, for use in clinical laboratories.
- COVID-19 Anti-S1 Total Ab Immunoturbidimetric test for quantitative and qualitative detection of total antibodies against the Spike RBD S1 protein of SARS-CoV-2 in human serum, run on SENTiFIT® analyzers in clinical laboratories.
- COVID-19 Anti-NC Total Ab Immunoturbidimetric test for quantitative and qualitative detection of total antibodies against the Nucleocapsid protein of SARS-CoV-2 in human serum, run on SENTiFIT® analyzers.
- STAT-NAT® VRE Lyophilized Real-Time PCR mix for rapid detection of Vancomycin-Resistant Enterococcus (VRE), identifying and differentiating vanA and vanB genes in a single tube, for use in clinical and hospital laboratories.
- STAT-NAT® virology kits Portfolio of lyophilized Real-Time PCR kits for virology applications including detection of HAdV, CMV, BKV, VZV, Parvo B19, HSV 1&2, HHV-6, HHV-7, HHV-8, EBV, and JCV, used by clinical laboratories.
- STAT-NAT® Leishmania spp. STAT-NAT® kit for molecular detection of Leishmania spp. parasites, used in clinical and parasitology laboratories.
- STAT-NAT® Pathomag extraction kit Magnetic beads-based nucleic acid extraction kit optimized for respiratory samples, enabling rapid purification of viral RNA/DNA and bacterial DNA, with 120 extractions per kit and room temperature storage.
- STAT-NAT® Total DNA/RNA extraction kit Extraction kit for isolating pathogen RNA and DNA, compatible with multiple clinical sample types and designed for high extraction efficiency at low viral titers, used by clinical laboratories.
- SENTiNAT® 200 Sample-to-result PCR platform and walk-away system with automatic result interpretation, designed for medium to high-throughput automated molecular diagnostics workflows in clinical laboratories.
- SENTiNAT® MICRO Compact PCR amplification instrument designed for manual molecular diagnostics workflows in clinical laboratory settings.
- SENTiNAT® X48 Automatic nucleic acid extraction and PCR set-up instrument used by clinical laboratories to prepare molecular diagnostics assays.
- SENTiFIT® 270 High-speed, fully automated quantitative analyzer for clinical chemistry and immunoturbidimetric assays, including FIT and serological tests, used in clinical laboratories.
- FOB Gold® Fecal Immunochemical Test (FIT) assay for colorectal cancer screening, run on SENTiFIT® automated analyzers in clinical laboratories.
- CALiaGold® Fecal Immunochemical Test (FIT) assay within the FIT product line, used for fecal immunochemical testing in clinical laboratories.
- PYLiaGold Fecal Immunochemical Test assay variant within the FIT product line, used for pepsinogen testing in clinical laboratories.
- Chromatography products (Eureka) Chromatography diagnostic kits acquired through the February 2023 acquisition of Eureka S.r.l., expanding Sentinel's diagnostic portfolio for clinical laboratories.
Companies that use Sentinel Diagnostics
Customer profileSegments2 records
Ideal customer profiles2 records
Sentinel Diagnostics technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Sentinel Diagnostics partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Eureka S.r.l.coreIn February 2023, Sentinel Diagnostics acquired Eureka S.r.l. to expand its diagnostic portfolio and assay offerings for clinical laboratories. This acquisition expanded Sentinel's product offerings in the chromatography space (referenced as www.eurekakit.com on their website).
Scale indicators2 records
Recent moves6 records
Expansion highlights4 records
Sentinel Diagnostics competitors and assessment
Company assessmentDirect peers
- ELITech Group: Mid-sized European IVD manufacturer offering molecular diagnostics (PCR) and clinical chemistry reagents to clinical laboratories — closely comparable scale and product structure to Sentinel.
- DiaSorin: Italian-headquartered IVD company with overlapping molecular diagnostics, clinical chemistry, and immunoassay product lines sold through clinical laboratories — direct European peer with similar customer base and product mix.
Broad incumbents
- Hologic: Diversified diagnostics player with Panther molecular diagnostic systems and assays targeting women's health, infectious disease, and HAIs — competes with Sentinel for clinical-lab molecular placements.
- Roche Diagnostics: World's largest IVD manufacturer covering molecular diagnostics, clinical chemistry, immunoassays, and laboratory automation — broadest incumbent reference benchmark for Sentinel's full portfolio.
- QIAGEN: Major provider of molecular diagnostics reagents, extraction kits, and PCR assays to clinical laboratories — directly competes in extraction and PCR reagent categories sold by Sentinel.
- bioMérieux: Global IVD leader with strong molecular diagnostics and clinical microbiology portfolios serving clinical laboratories — broad incumbent competing on respiratory panels, HAIs, and reagents.
- Cepheid (Danaher): Global leader in sample-to-result molecular diagnostics (GeneXpert) for infectious disease and healthcare-associated infections — competes head-to-head with SENTiNAT and STAT-NAT in clinical-lab molecular IVD.
- Abbott Diagnostics: Global IVD leader with molecular (m2000, Alinity m), immunoassay, and clinical chemistry systems — competes across Sentinel's menu with clinical-laboratory customers.
Emerging players
- Seegene: Molecular diagnostics company specializing in multiplex syndromic PCR assays (respiratory, gastrointestinal) — comparable technology overlap with Sentinel's STAT-NAT multiplex panels.
Regional players
- Eurospital: Italian diagnostics manufacturer producing IVD reagents and clinical chemistry products for Italian and European clinical laboratories — comparable regional scale and end-market focus.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Sentinel Diagnostics social profiles
Digital presenceSentinel Diagnostics compliance and trust
Trust signalCompliance8 records
Sentinel Diagnostics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Sentinel Diagnostics leadership team
Management profileNumber of profiles
Profiles1 record
Sentinel Diagnostics subsidiaries and ownership
Company hierarchySubsidiaries1 record
Sentinel Diagnostics funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Sentinel Diagnostics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Sentinel Diagnostics
What does Sentinel Diagnostics do?
Sentinel Diagnostics researches, develops, and manufactures In Vitro Diagnostic (IVD) medical devices for clinical laboratories. Its portfolio includes proprietary lyophilized real-time PCR kits (STAT-NAT®) for molecular diagnostics, fecal immunochemical tests (FIT line) for colorectal cancer screening, clinical chemistry reagents, and automated instruments (SENTiNAT®, SENTiFIT®). Products are sold directly to clinical laboratories and healthcare facilities, primarily in the EU and selected international markets.
Is Sentinel Diagnostics a public or private company?
Sentinel Diagnostics is a private company. It is classified as unknown and is currently operating.
When was Sentinel Diagnostics founded?
Sentinel Diagnostics was founded in 2009. It employs 101 to 250 people.
Where is Sentinel Diagnostics based?
Sentinel Diagnostics is headquartered in Milano, Italy, in the Europe region.
How does Sentinel Diagnostics make money?
One revenue line is on record: IVD Products Manufacturing and Sales.
Who are Sentinel Diagnostics's main competitors?
Direct peers on record are ELITech Group and DiaSorin. Broad incumbents are Hologic, Roche Diagnostics, QIAGEN, bioMérieux, Cepheid (Danaher) and Abbott Diagnostics. Seegene is listed as an emerging player. Eurospital is listed as a regional player.
Does Sentinel Diagnostics have an API?
No public API is recorded for Sentinel Diagnostics.
What industry is Sentinel Diagnostics in?
Sentinel Diagnostics's product category is In Vitro Diagnostics. Its primary akta.pro industry code is HLAHAAAM, IVD Reagents, Assay Kits & Consumables (Non-instrument), with a secondary code of HLAAAMAL, Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls). Its NAICS code is 325413 and its SIC code is 2835.